LEGN · NASDAQ · STOCK
Legend Biotech (LEGN) Stock Analysis
$18.64
52W $16.24 – $37.50
63/100
$3.44B
-37.2
0.40
Is LEGN Bullish or Bearish?
Bullish.
Innellis AI committee rates Legend Biotech Corporation (LEGN) Buy with a composite score of 63/100
, based on 5 analysts with 60% agreement.
Last updated October 10, 2026.
What Would Change This View
- Upgrade to Strong Buy
- Requires a committee score of 75.0 — +11.92 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Watch
- Requires the score to fall below 55.0 — -8.08 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Growth Analyst sees a compelling case — revenue growing 59.6% yoy -- genuine top-line momentum. Portfolio Manager remains cautious — sector concentration is already high (hhi 2796.97). This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- Revenue growing 59.6% YoY -- genuine top-line momentum — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
- Weekly trend (downtrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- ROE of only -8.7% -- cheap may mean cheap for a reason — Value
- Price structure making lower highs and lower lows — Technical
- Trend and market structure agree -- coherent bearish picture — Technical
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of October 10, 2026
Overall Committee Score
63/100
Agreement
60%
Analysts
5
Conviction
Moderate
Sector Rank
Top 13%
of 192 Healthcare peers
Value Analyst
neutral
52
/ 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
− ROE of only -8.7% -- cheap may mean cheap for a reason
Growth Analyst
bullish
85
/ 100 · Moderate confidence
Strong, accelerating growth with consistent execution
+ Revenue growing 59.6% YoY -- genuine top-line momentum
Technical Analyst
neutral
56
/ 100 · High confidence
Mixed or range-bound price action
+ MACD histogram positive -- bullish momentum
− Price structure making lower highs and lower lows
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
neutral
58
/ 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
Portfolio Manager
bearish
30
/ 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Investment Thesis Evolution
Committee score moved marginally from 63.1 to 63.1.
Comparing 2026-10-09 to 2026-10-10 (1 day apart).
Technical Analysis
RSI (14)
45.1
Neutral
MACD Histogram
0.106
Bullish Momentum
Trend Direction
Downtrend
Weekly: Downtrend
Market Structure
Lh Ll
Support
$18.33
Resistance
$21.54
Bollinger %B
0.53
Inside Bands
Price vs Moving Averages
EMA 9
$18.83
Below
EMA 21
$19.03
Below
EMA 50
$20.21
Below
EMA 200
$23.64
Below
Fundamental Analysis
Valuation
93
Growth
60
Profitability
23
Financial Health
100
Cash Flow
15
Valuation
P/E Ratio
-37.2×
P/B Ratio
2.83×
PEG Ratio
-0.45
Dividend Yield
0.00%
52W High
$37.50
52W Low
$16.24
Quality & Growth
ROE
-2961.8%
ROA
-1711.9%
Gross Margin
5657.5%
Operating Margin
-441.7%
Revenue Growth YoY
—
Debt / Equity
0.23
AI Fundamental Assessment
P/E ratio of -37.2 (inexpensive relative to a 15-40x range); Price-to-book of 2.8x; PEG ratio of -0.5 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -29.6%; Return on assets of -17.1%; Net margin of -7.2%; Gross margin of 56.6%; Current ratio of 3.04 (healthy short-term liquidity); Debt-to-equity of 0.23; Free cash flow per share is negative (-1.37); Most recent quarter beat estimates by 135.6%; EPS growth accelerating (-87.5% -> +160.0% QoQ); Analyst estimates rising over recent quarters
Get the Full LEGN Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →